A detailed history of Park Place Capital Corp transactions in Genmab A/S stock. As of the latest transaction made, Park Place Capital Corp holds 156 shares of GMAB stock, worth $3,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares
156
Previous 2,853 94.53%
Holding current value
$3,212
Previous $71,000 95.77%
% of portfolio
0.0%
Previous 0.02%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$23.84 - $28.48 $64,296 - $76,810
-2,697 Reduced 94.53%
156 $3,000
Q2 2024

Jul 02, 2024

SELL
$25.13 - $30.27 $59,331 - $71,467
-2,361 Reduced 45.28%
2,853 $71,000
Q1 2024

Apr 18, 2024

BUY
$26.43 - $32.77 $8,536 - $10,584
323 Added 6.6%
5,214 $155,000
Q4 2023

Jan 24, 2024

BUY
$27.94 - $35.44 $14,947 - $18,960
535 Added 12.28%
4,891 $155,000
Q3 2023

Oct 17, 2023

BUY
$35.27 - $42.24 $2,645 - $3,168
75 Added 1.75%
4,356 $153,000
Q2 2023

Aug 04, 2023

SELL
$37.4 - $42.94 $13,875 - $15,930
-371 Reduced 7.98%
4,281 $162,000
Q1 2023

May 02, 2023

SELL
$34.88 - $43.22 $9,208 - $11,410
-264 Reduced 5.37%
4,652 $175,000
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $166,160 - $231,346
4,916 New
4,916 $208,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Park Place Capital Corp Portfolio

Follow Park Place Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Place Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Park Place Capital Corp with notifications on news.